Loerop James's most recent trade in Aclaris Therapeutics Inc was a trade of 20,875 Common Stock done . Disclosure was reported to the exchange on Feb. 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2026 | 20,875 | 198,197 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2026 | 20,875 | 62,625 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.47 per share. | 03 Feb 2026 | 5,937 | 192,260 (0%) | 0% | 3.5 | 20,601 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 341,900 | 341,900 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 97,700 | 97,700 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 01 Feb 2026 | 15,980 | 102,773 (0%) | 0% | 2.5 | 39,630 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2026 | 14,750 | 29,500 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2026 | 14,750 | 188,008 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2026 | 11,250 | 165,758 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2026 | 11,250 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.51 per share. | 01 Feb 2026 | 10,686 | 177,322 (0%) | 0% | 3.5 | 37,508 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2026 | 7,500 | 173,258 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2026 | 7,500 | 7,500 | - | - | Resticted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 73,750 | 177,056 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 73,750 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.01 per share. | 31 Dec 2025 | 33,994 | 143,062 (0%) | 0% | 3.0 | 102,322 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 18,150 | 161,212 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 18,150 | 18,700 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.88 per share. | 31 Dec 2025 | 6,171 | 155,041 (0%) | 0% | 2.9 | 17,772 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 292,300 | 292,300 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 83,500 | 83,500 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 01 Feb 2025 | 15,980 | 102,773 (0%) | 0% | 2.5 | 39,630 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 01 Feb 2025 | 15,447 | 103,306 (0%) | 0% | 2.5 | 38,309 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 14,750 | 44,250 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 14,750 | 118,753 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 11,250 | 96,503 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 11,250 | 11,250 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 7,500 | 104,003 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 7,500 | 15,000 | - | - | Resticted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 73,750 | 107,767 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 73,750 | 73,750 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 55,000 | 55,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 31 Dec 2024 | 32,089 | 75,678 (0%) | 0% | 2.5 | 79,581 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 18,150 | 36,850 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 18,150 | 93,828 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 31 Dec 2024 | 8,575 | 85,253 (0%) | 0% | 2.5 | 21,266 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 206,500 | 206,500 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Loerop James | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 147,500 | 147,500 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Loerop James | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 59,000 | 59,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 11,250 | 32,938 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 11,250 | 22,500 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Loerop James | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 7,500 | 36,585 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 7,500 | 22,500 | - | - | Restricted Stock Unit | |
| Aclaris Therapeutics Inc | Loerop James | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.20 per share. | 01 Feb 2024 | 3,853 | 29,085 (0%) | 0% | 1.2 | 4,624 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.20 per share. | 01 Feb 2024 | 2,568 | 34,017 (0%) | 0% | 1.2 | 3,082 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 6.80 per share. | 28 Aug 2023 | 14,705 | 21,688 (0%) | 0% | 6.8 | 99,959 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 13.89 per share. | 08 Feb 2023 | 4,267 | 6,983 (0%) | 0% | 13.9 | 59,272 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 105,000 | 105,000 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 30,000 | 30,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 11,250 | 33,750 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 11,250 | 11,250 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 155,000 | 155,000 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 45,000 | 45,000 | - | - | Restricted Stock Units | |
| Anika Therapeutics Inc | James Loerop | EVP Business Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2021 | 3,000 | 3,000 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc | James Loerop | EVP Business Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2021 | 3,000 | 6,323 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc | James Loerop | EVP Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.24 per share. | 08 Jul 2021 | 731 | 5,592 (0%) | 0% | 43.2 | 31,608 | Common Stock |